Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ACTRN12626000838314) titled 'A study of the safety, tolerability and immune cell profile of one dose of Activated Immune Cells with Anti-Cancer Phenotype in healthy volunteers' on July 10.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Masking: Open (masking not used)
Assignment: Single group
Type of endpoint: Safety
Primary Sponsor: Aeterna Health Services PTY LTD
Condition:
Cancer
Cancer
Cancer - Any cancer
Intervention:
This study will assess the safety, tolerability and immune cell profile of one dose of Activated Immune Cells with Anti-Cancer Phenotype in healthy volunteers.
Each...